Semma Therapeutics Stock

semma-tx.comHealthcare / BioTech & PharmaFounded: 2014Funding to Date: $158MM

Developer of trans-formative therapies designed to eliminate the use of insulin injections for type 1 diabetes patients. The company's trans-formative therapies is a cell-based therapy for diabetes which traditionally requires the use of an invasive insulin pump or multiple daily insulin injections combining proprietary cells with a state-of-the-art device to provide a replacement for the missing beta cells in a diabetic patient without immunosuppression, enabling doctors to provide a functional cure for patients with diabetes.

Register To Buy and Sell Shares

For more details on financing and valuation for Semma Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Semma Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Semma Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Mary Fenton
Chief Financial Officer
Felicia Pagliuca Ph.D
Vice President, Cell Biology and Research & Development and Co-Founder
Jason Gaglia
Vice President, Clinical Sciences
Jeff Imbaro
Vice President, Operations and Alliances
Bastiano Sanna Ph.D
Chief Executive Officer & President
Briannan Bintz
Director of Delivery
Christopher Thanos Ph.D
Vice President, Delivery
David Lebwohl MD
Chief Medical Officer
David DiGiusto Ph.D
Chief Technical Officer
Douglas Melton Ph.D
Scientific Co-Founder and Board Observer
Walter Blattler Ph.D
Vice President, Manufacturing

Board Members

Douglas Melton Ph.D
James Scopa JD
MPM Capital
Stephen Knight MD
F-Prime Capital Partners
William Sahlman Ph.D
David Neustaedter Ph.D
Medtronic
Kevin Raidy
Cowen Group
Mitchell Finer Ph.D
MPM Capital
Daniel Auerbach
Eight Roads
Mark Fishman MD
Todd Foley
MPM Capital

Frequently Asked Questions About Semma Therapeutics’ Stock

plusminus
Can you buy Semma Therapeutics’ stock?
Semma Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Semma Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Semma Therapeutics’ stock?
Yes, you can sell stock of a private company like Semma Therapeutics. Forge can help you sell your Semma Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Semma Therapeutics’ stock price?
Semma Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Semma Therapeutics’ private market stock price with Forge Data.
plusminus
What is Semma Therapeutics’ stock ticker symbol?
Semma Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.
Updated on: Feb 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.